Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
Richard A. Furie, Maria Dall'Era, Edward M J Vital, Jay P Garg et autres
BACKGROUND: Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, induces potent B-cell depletion and is approved for the treatment of active lupus nephritis. Its efficacy and safety in patients with active systemic lupus erythematosus (SLE) are yet to be determined. METHODS: We …
us, gb, pe, br, mx, Afrique du Sud, pl, fr, it, nz, ca, ch (code pays fourni par la source)